Safety of apremilast: risk of psychical disorders

Safety of apremilast: risk of psychical disorders

Apremilast is a new selective inhibitor of phosphodiesterase 4 (PDE4) of the class of small molecules, approved for treatment of psoriatic arthritis and psoriasis. The efficacy and safety of apremilast in the treatment of moderate to severe plaque psoriasis have been demonstrated in multicenter, ran...

Full description

Bibliographic Details
Main Authors: T. M. Bukatina, N. Yu. Velts, M. A. Darmostukova, E. Yu. Pasternak, T. V. Romanova
Format: Article
Language:Russian
Published: Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation  2018-02-01
Series:Безопасность и риск фармакотерапии
Subjects:
ингибиторы фосфодиэстеразы 4
препараты класса малых молекул
апремиласт
нарушения психики
суицидальные мысли
суицидальные наклонности
суицидальное поведение
inhibitors of phosphodiesterase 4
aprimilast
psychical disorders
suicidal ideation
suicide attempt
completed suicide
suicidal behavior
Online Access:https://www.risksafety.ru/jour/article/view/89

Internet

https://www.risksafety.ru/jour/article/view/89

Similar Items